Pazopanib based combination oral metronomic therapy in platinum resistant, platinum refractory and advanced ovarian cancer : A Randomized Phase 2 Study
Latest Information Update: 10 Jun 2021
Price :
$35 *
At a glance
- Drugs Pazopanib (Primary) ; Cyclophosphamide; Etoposide
- Indications Carcinoma; Ovarian cancer
- Focus Therapeutic Use
- 01 Jun 2021 Status changed to completed according to Results published in the Gynecologic Oncology
- 01 Jun 2021 Primary endpoint (To assess the Serological Progression free survival (PFS)) , has been met according to Results published in the Gynecologic Oncology
- 01 Jun 2021 Results published in the Gynecologic Oncology